ONCASPAR Side Effects

7019669-0 | Ketoacidosis, Neutropenia
on Sep 28, 2010 Female patient from UNITED STATES , 29 years of age, weighting 141.1 lb, was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: ketoacidosis, neutropenia. Oncaspar dosage: .

6994672-5 | Aspergillosis, Empyema, Pleural Effusion, Pneumothorax, Pulmonary Embolism, Pulmonary Infarction, Pulmonary Necrosis, Pyrexia
Patient was taking Oncaspar (View Usage). Patient had the following side effects: aspergillosis, empyema, pleural effusion, pneumothorax, pulmonary embolism (What is pulmonary embolism?), pulmonary infarction, pulmonary necrosis, pyrexia on Sep 03, 2010 from CANADA Additional patient health information: Male patient , 45 years of age, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 6125 Iu;x1 ;iv. During the same period patient was treated with DOXORUBICIN HCL (73.5 Mg;qd;iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (2 Mg;qw;iv) (View Vincristine Review and Vincristine Label ), METHYLPREDNISOLONE (2 Mg;qw;iv) (View Methylprednisolone Review and Methylprednisolone Label ), PREDNISONE (40 Mg/m2;qd;po) (View Prednisone Review and Prednisone Label ), CYTARABINE (50 Mg;x1;iv) (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (98 Mg;x1;iv, 12 Mg X1;inth) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6971741-7 | Dehydration, Fluid Intake Reduced, Vomiting
Adverse event was reported on Aug 25, 2010 by a Female patient taking Oncaspar (View Usage) (Dosage: 4425 Mg; X1; Iv) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 16 years of age, weighting 153.0 lb, After Oncaspar was administered, patient had the following side effects: dehydration, fluid intake reduced, vomiting. During the same period patient was treated with DAUNORUBICIN HCL (90 Mg; Qw; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (15 Mg; X1; Inth) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (840 Mg; Bid; Po) (View Prednisone Review and Prednisone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6946188-X | Blood Fibrinogen Decreased, Gallbladder Disorder, Hepatic Steatosis, Hypercholesterolaemia, Hyperglycaemia, Hypertriglyceridaemia, International Normalised Ratio Increased
on Aug 10, 2010 Male patient from UNITED STATES , 16 years of age, weighting 227.1 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood fibrinogen decreased, gallbladder disorder, hepatic steatosis, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, international normalised ratio increased. Oncaspar dosage: 6050 Iu; X1; Iv, 5637.5 Iu; X1; Iv. During the same period patient was treated with DAUNORUBICIN HCL (240 Mg; ; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (8 Mg; ; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), PREVACID (View Prevacid Review and Prevacid Label ), MERCAPTOPURINE (3800 Mg; ; Po) (View Mercaptopurine Review and Mercaptopurine Label ). Patient was hospitalized.


6938768-2 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Fibrinogen Decreased, Gallbladder Disorder, Gamma-glutamyltransferase Increased, Hepatic Steatosis, Hyperbilirubinaemia, Hypercholesterolaemia, Hyperglycaemia
on Aug 10, 2010 Male patient from UNITED STATES , 16 years of age, weighting 227.1 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood fibrinogen decreased, gallbladder disorder, gamma-glutamyltransferase increased, hepatic steatosis, hyperbilirubinaemia, hypercholesterolaemia, hyperglycaemia. Oncaspar dosage: 6050 Iu;x1;i V, 5637.5 Iu; X1; Iv. During the same period patient was treated with DAUNORUBICIN HCL (240 Mg; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (8 Mg; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), PREVACID (View Prevacid Review and Prevacid Label ), MERCAPTOPURINE (3800 Mg; Po) (View Mercaptopurine Review and Mercaptopurine Label ). Patient was hospitalized.

6932981-6 | Anxiety, Fall, Fatigue, Grand Mal Convulsion, Haemorrhage Intracranial, Head Injury, Muscular Weakness
Patient was taking Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: anxiety (What is anxiety?), fall (What is fall?), fatigue, grand mal convulsion, haemorrhage intracranial, head injury, muscular weakness on Aug 04, 2010 from UNITED STATES Additional patient health information: Male patient , 31 years of age, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 2500 Iu/m*2; X1; Iv. During the same period patient was treated with CYTARABINE (50 Mg; X1; Inth) (View Cytarabine Review and Cytarabine Label ), VINCRISTINE (2 Mg;qd;iv) (View Vincristine Review and Vincristine Label ), METHYLPREDNISOLONE (20 Mg;q8h;iv) (View Methylprednisolone Review and Methylprednisolone Label ), DOXORUBICIN HCL (50 Mg;qd;iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (40 Mg;bid;po) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6931455-6 | Abdominal Pain, Asthenia, Blood Albumin Decreased, Diarrhoea, Dizziness, Hypocalcaemia, Hypophosphataemia, Hypotension, Pyrexia
Adverse event was reported on Aug 02, 2010 by a Female patient taking Oncaspar (View Usage) (Dosage: 4750 Iu;x1;im) was diagnosed with b precursor type acute leukaemia and. Location: UNITED STATES , child 12 years of age, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), asthenia, blood albumin decreased, diarrhoea, dizziness (What is dizziness?), hypocalcaemia, hypophosphataemia, hypotension, pyrexia. During the same period patient was treated with SPRYCEL (1540 Mg;po) (View Sprycel Review and Sprycel Label ), DAUNORUBICIN HCL (188 Mg;iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), PREDNISONE (2484 Mg;po) (View Prednisone Review and Prednisone Label ), VINCRISTINE (8 Mg;iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6929576-7 | Abdominal Pain Lower, Back Pain, Blood Phosphorus Increased, Hyperbilirubinaemia, Hyperglycaemia, Hyperuricaemia, Hypoalbuminaemia, Hypocalcaemia, International Normalised Ratio Increased
on Aug 03, 2010 Male patient from UNITED STATES , 17 years of age, weighting 146.4 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: abdominal pain lower, back pain (What is back pain?), blood phosphorus increased, hyperbilirubinaemia, hyperglycaemia, hyperuricaemia, hypoalbuminaemia, hypocalcaemia, international normalised ratio increased. Oncaspar dosage: 2500 Iu*m2; Iv, 4500 Iu;x1; Iv. During the same period patient was treated with METHOTREXATE (15 Mg; Inth, 810 Mg; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (6 Mg; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6914875-5 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Decreased, Blood Fibrinogen Decreased, Gallbladder Disorder, Gamma-glutamyltransferase Increased, Hepatic Steatosis, Hepatomegaly, Hyperbilirubinaemia, Hypercholesterolaemia
on Jul 23, 2010 Male patient from UNITED STATES , 16 years of age, weighting 227.1 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase decreased, blood fibrinogen decreased, gallbladder disorder, gamma-glutamyltransferase increased, hepatic steatosis, hepatomegaly, hyperbilirubinaemia, hypercholesterolaemia. Oncaspar dosage: 6050 Mg; X1; Iv. During the same period patient was treated with DAUNORUBICIN HCL (240 Mg; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (8 Mg; ; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), PREVACID (View Prevacid Review and Prevacid Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6905221-1 | Abdominal Pain Upper, Asthenia, Febrile Neutropenia, Hyperbilirubinaemia, Hypercholesterolaemia, Hyperglycaemia, Hypertriglyceridaemia, Hypoglycaemia, Hypophagia
Patient was taking Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, asthenia, febrile neutropenia, hyperbilirubinaemia, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hypoglycaemia, hypophagia on Jul 21, 2010 from UNITED STATES Additional patient health information: Female patient , 13 years of age, weighting 144.0 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 4750 Iu; X1; Iv, 3750 Iu; X1; Iv. During the same period patient was treated with PREDNISONE (3360 Mg; Bid; Po) (View Prednisone Review and Prednisone Label ), DAUNORUBICIN HCL (160 Mg; Qw; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (30 Mg; ; Inth, 60 Mg; ; Inth) (View Methotrexate Review and Methotrexate Label ), CYTARABINE (70 Mg; X1; Inth, 2080 Mg; ; Iv) (View Cytarabine Review and Cytarabine Label ), VINCRISTINE (7.9 Mg; ; Iv, 8 Mg; ; Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6797367-6 | Activated Partial Thromboplastin Time Prolonged, Anaemia, Dehydration, Haematemesis, Hyperbilirubinaemia, Hyperglycaemia, Leukopenia, Mucosal Inflammation, Oral Pain
Adverse event was reported on Jun 11, 2010 by a Male patient taking Oncaspar (View Usage) (Dosage: 3575 Iu;x1;iv, 3300 Iu;x1;iv, 3300 Iu;x1;iv) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 9 years of age, weighting 95.02 lb, Patient had the following side effects: activated partial thromboplastin time prolonged, anaemia, dehydration, haematemesis, hyperbilirubinaemia, hyperglycaemia, leukopenia, mucosal inflammation, oral pain. During the same period patient was treated with METHOTREXATE (130 Mg;x1;iv, 15 Mg;x1;inth, 80 Mg;x1;iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6782873-0 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Fibrinogen Decreased, Gallbladder Disorder, Gamma-glutamyltransferase Increased, Hepatic Steatosis, Hyperbilirubinaemia, Hypercholesterolaemia, Hyperglycaemia
on Jun 02, 2010 Male patient from UNITED STATES , 16 years of age, weighting 227.1 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood fibrinogen decreased, gallbladder disorder, gamma-glutamyltransferase increased, hepatic steatosis, hyperbilirubinaemia, hypercholesterolaemia, hyperglycaemia. Oncaspar dosage: 6050 Mg;x1;iv. During the same period patient was treated with DAUNORUBICIN HCL (240 Mg;iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (8 Mg;iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), PREVACID (View Prevacid Review and Prevacid Label ), CYTRABINE (View Cytrabine Review and Cytrabine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6765225-9 | Blood Pressure Decreased, Chills, Glycosylated Haemoglobin Increased, Grand Mal Convulsion, Headache, Hypertension, Hyponatraemia, Infusion Site Extravasation, Pyrexia
on Jun 10, 2010 Female patient from UNITED STATES , weighting 103.6 lb, was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, chills, glycosylated haemoglobin increased, grand mal convulsion, headache (What is headache?), hypertension, hyponatraemia, infusion site extravasation, pyrexia. Oncaspar dosage: 70 Mg. During the same period patient was treated with DAUNORUBICIN HCL (105 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (15 Mg) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (1200 Mg) (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (6 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6740763-3 | Activated Partial Thromboplastin Time Prolonged, Anaemia, Dehydration, Haematemesis, Hyperbilirubinaemia, Hyperglycaemia, Leukopenia, Mucosal Inflammation, Oral Pain
Patient was taking Oncaspar (View Usage). Patient had the following side effects: activated partial thromboplastin time prolonged, anaemia, dehydration, haematemesis, hyperbilirubinaemia, hyperglycaemia, leukopenia, mucosal inflammation, oral pain on May 13, 2010 from UNITED STATES Additional patient health information: Male patient , child 9 years of age, weighting 95.02 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 3575 Iu; X1; Iv, 3300 Iu; X1; Iv. During the same period patient was treated with METHOTREXATE (130 Iu; X1; Iv, 15 Mg; X1; Inth, 80 Iu; X1; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6737619-9 | Abdominal Discomfort, Cerebrovascular Accident, Constipation, Nausea, Pain
Adverse event was reported on May 21, 2010 by a Male patient taking Oncaspar (View Usage) (Dosage: ) . Location: UNITED STATES , 22 years of age, weighting 141.8 lb, After Oncaspar was administered, patient had the following side effects: abdominal discomfort, cerebrovascular accident, constipation (What is constipation?), nausea (What is nausea?), pain (What is pain?). Patient was hospitalized and became disabled.

6737548-0 | Urticaria
on May 21, 2010 Female patient from UNITED STATES , weighting 22.49 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: urticaria. Oncaspar dosage: 1225 I.u. Q8weeks I.m.. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6730493-6 | Bacillus Infection, Brain Herniation, Hypotension, Nervous System Disorder, Refractoriness To Platelet Transfusion, Respiratory Failure, Sepsis, Thrombocytopenia
on May 11, 2010 Female patient from UNITED STATES , 42 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: bacillus infection, brain herniation, hypotension, nervous system disorder, refractoriness to platelet transfusion, respiratory failure, sepsis (What is sepsis?), thrombocytopenia. Oncaspar dosage: 2500 Iu/m2; X1; Iv. During the same period patient was treated with PREDNISONE TAB (40 Mg/m**2; Bid; Po) (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE (2 Mg; X1; Iv) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (30 Mg; Qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (40 Mg; X1; Iv) (View Methotrexate Review and Methotrexate Label ), CYTARABINE (50 Mg; X1; Inth) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6727741-5 | Acidosis, Bradycardia, Cardiac Arrest, Hypernatraemia, Multi-organ Failure, Pancytopenia, Septic Shock, Stenotrophomonas Infection
Patient was taking Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: acidosis, bradycardia, cardiac arrest (What is cardiac arrest?), hypernatraemia, multi-organ failure, pancytopenia, septic shock, stenotrophomonas infection on May 14, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 147.7 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 4400 Iu Once Per Cycle Iv Drip. During the same period patient was treated with NOREEPINEPHRINE (View Noreepinephrine Review and Noreepinephrine Label ), VASOPRESSIN (View Vasopressin Review and Vasopressin Label ), PRESSORS (View Pressors Review and Pressors Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ), MOXIFLOXACIN (View Moxifloxacin Review and Moxifloxacin Label ). Patient was hospitalized.

6719454-0 | Bacillus Infection, Brain Herniation, Hypotension, Nervous System Disorder, Refractoriness To Platelet Transfusion, Respiratory Failure, Sepsis, Thrombocytopenia
Adverse event was reported on Apr 23, 2010 by a Female patient taking Oncaspar (View Usage) (Dosage: 2500 Iu/m2, X1;iv) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 42 years of age, Patient experienced the following unwanted or unexpected effects: bacillus infection, brain herniation, hypotension, nervous system disorder, refractoriness to platelet transfusion, respiratory failure, sepsis (What is sepsis?), thrombocytopenia. During the same period patient was treated with PREDNISONE TAB (40 Mg/m**2;bid; Po) (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE (2mg; X1;iv) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (30 Mg; Qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (40 Mg;x1; Iv) (View Methotrexate Review and Methotrexate Label ), CYTARABINE (50 Mg;x1; Inth) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6697693-5 | Anaemia, Decreased Appetite, Dehydration, Haematemesis, Hyperbilirubinaemia, Hyperglycaemia, Leukopenia, Mucosal Inflammation, Oropharyngeal Pain
on Apr 14, 2010 Male patient from UNITED STATES , child 9 years of age, weighting 95.02 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: anaemia, decreased appetite, dehydration, haematemesis, hyperbilirubinaemia, hyperglycaemia, leukopenia, mucosal inflammation, oropharyngeal pain. Oncaspar dosage: 3575 Iu; X1; Iv, 3300 Iu; X1; Iv. During the same period patient was treated with METHOTREXATE (130 Mg; X1; Iv, 15 Mg; X1; Inth, 80 Mg; X1; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6693349-3 | Anoxic Encephalopathy, Arteriosclerosis Coronary Artery, Brain Contusion, Bronchopneumonia, Cardiac Arrest, Coma, Fall, Fat Necrosis
on Apr 07, 2010 Male patient from UNITED STATES , 60 years of age, weighting 173.7 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: anoxic encephalopathy, arteriosclerosis coronary artery, brain contusion, bronchopneumonia, cardiac arrest (What is cardiac arrest?), coma, fall (What is fall?), fat necrosis. Oncaspar dosage: 2500 Iu/kg:x1;iv ; 2500 Iu/kg;iv. During the same period patient was treated with CALCIUM (View Calcium Review and Calcium Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), FLONASE (View Flonase Review and Flonase Label ), IMATINIB (View Imatinib Review and Imatinib Label ), PREVACID (View Prevacid Review and Prevacid Label ), CLARITIN (View Claritin Review and Claritin Label ). Patient was hospitalized.

6676340-2 | Pulmonary Embolism, Renal Infarct
Patient was taking Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?), renal infarct on Mar 29, 2010 from UNITED STATES Additional patient health information: Female patient , 60 years of age, weighting 172.0 lb, was diagnosed with b precursor type acute leukaemia and. Oncaspar dosage: 4625 Iu;x1;iv, 4500 Iu; X1; Iv, 4400 Iu;x1;iv. During the same period patient was treated with PROGESTERONE (100 Mg;qd;po) (View Progesterone Review and Progesterone Label ), VIVELLE (0.1 Mg;qd;po) (View Vivelle Review and Vivelle Label ). Patient was hospitalized.

6676263-9 | Activated Partial Thromboplastin Time Prolonged, Ascites, Constipation, Disseminated Intravascular Coagulation, Hyperbilirubinaemia, Hyperglycaemia, Pancreatitis Necrotising, Pleural Effusion, Pneumomediastinum
Adverse event was reported on Mar 25, 2010 by a Female patient taking Oncaspar (View Usage) (Dosage: 4425 Iu; X1; Iv) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 15 years of age, weighting 153.0 lb, Patient had the following side effects: activated partial thromboplastin time prolonged, ascites, constipation (What is constipation?), disseminated intravascular coagulation, hyperbilirubinaemia, hyperglycaemia, pancreatitis necrotising, pleural effusion, pneumomediastinum. During the same period patient was treated with PREDNISONE (2625 Mg; Bid; Po) (View Prednisone Review and Prednisone Label ), DAUNORUBICIN HCL (135 Mg; Iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (6 Mg; Iv) (View Vincristine Review and Vincristine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6663801-5 | Pancreatitis
on Feb 19, 2009 Female patient from UNITED STATES , child 12 years of age, weighting 70.55 lb, was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: pancreatitis. Oncaspar dosage: . Patient was hospitalized.

6663070-6 | Dyspnoea, Hypersensitivity, Loss Of Consciousness
on Dec 24, 2009 Male patient from UNITED STATES , 19 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, hypersensitivity, loss of consciousness. Oncaspar dosage: . During the same period patient was treated with APAP W/ CODEINE (View Apap W/ Codeine Review and Apap W/ Codeine Label ), ZOFRAN (View Zofran Review and Zofran Label ), COMPAZINE (View Compazine Review and Compazine Label ), NASONEX (View Nasonex Review and Nasonex Label ), CIPRO (View Cipro Review and Cipro Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ). Patient was hospitalized.

6663069-X | Hypersensitivity, Pharyngeal Oedema, Throat Irritation, Urticaria
Patient was taking Oncaspar (View Usage). Patient had the following side effects: hypersensitivity, pharyngeal oedema, throat irritation, urticaria on Sep 15, 2009 from UNITED STATES Additional patient health information: Male patient , 13 years of age, weighting 207.2 lb, was diagnosed with leukaemia and. Oncaspar dosage: 5000 Iu; Im. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6663068-8 | Hypersensitivity, Pruritus, Urticaria
Adverse event was reported on Sep 15, 2009 by a Female patient taking Oncaspar (View Usage) (Dosage: 2200 Iu; Im) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 6 years of age, weighting 50.71 lb, After Oncaspar was administered, patient had the following side effects: hypersensitivity, pruritus, urticaria. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), SEPTRA (View Septra Review and Septra Label ), NYSTATIN (View Nystatin Review and Nystatin Label ).

6663067-6 | Hypersensitivity, Pruritus, Rash, Urticaria
on Sep 15, 2009 Female patient from UNITED STATES , 15 years of age, weighting 143.3 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: hypersensitivity, pruritus, rash (What is rash?), urticaria. Oncaspar dosage: 4375 Iu; X1; Im. During the same period patient was treated with PLATELETS (;x1; Iv) (View Platelets Review and Platelets Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

6663066-4 | Chest Discomfort, Chest Pain, Hypersensitivity, Nausea, Pruritus, Tachycardia
on Jul 07, 2009 Male patient from UNITED STATES , 26 years of age, weighting 324.1 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: chest discomfort, chest pain (What is chest pain?), hypersensitivity, nausea (What is nausea?), pruritus, tachycardia. Oncaspar dosage: 4500 Iu; Im : 4500 Iu; Iv. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ANZEMET (View Anzemet Review and Anzemet Label ).

6663065-2 | Anaphylactic Reaction, Dyspnoea, Urticaria
Patient was taking Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: anaphylactic reaction, dyspnoea, urticaria on May 27, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 121.5 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: ; X1 ; Im. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6663063-9 | Anaphylactic Reaction, Auricular Swelling, Paraesthesia, Pharyngeal Oedema, Pruritus
Adverse event was reported on May 27, 2009 by a Male patient taking Oncaspar (View Usage) (Dosage: ; Im) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 13 years of age, weighting 120.2 lb, Patient experienced the following unwanted or unexpected effects: anaphylactic reaction, auricular swelling, paraesthesia, pharyngeal oedema, pruritus. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6663061-5 | Anaphylactic Reaction, Dyspnoea, Neutrophil Count Decreased, Throat Tightness, Wheezing, White Blood Cell Count Decreased
on Mar 26, 2009 Female patient from UNITED STATES , 16 years of age, weighting 133.2 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: anaphylactic reaction, dyspnoea, neutrophil count decreased, throat tightness, wheezing, white blood cell count decreased. Oncaspar dosage: 4050 Iu; Iv. During the same period patient was treated with TYLENOL 500 (View Tylenol-500 Review and Tylenol-500 Label ), BENADRYL (View Benadryl Review and Benadryl Label ), ZOFRAN (View Zofran Review and Zofran Label ), DECADRON (View Decadron Review and Decadron Label ), BACTRIM (View Bactrim Review and Bactrim Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), PEG 3350 (View Peg-3350 Review and Peg-3350 Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6663059-7 | Anaphylactic Reaction, Exophthalmos, Flushing, Screaming
on Mar 27, 2009 Male patient from UNITED STATES , child 5 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: anaphylactic reaction, exophthalmos, flushing, screaming. Oncaspar dosage: ;iv.

6663058-5 | Blood Bilirubin Increased, Liver Function Test Abnormal
Patient was taking Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, liver function test abnormal on Feb 26, 2009 from UNITED STATES Additional patient health information: Female patient , 77 years of age, weighting 125.7 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 3961 Iu;x1;iv. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), MULTI VITAMINS (View Multi-vitamins Review and Multi-vitamins Label ). Patient was hospitalized.

6663057-3 | Pancreatitis
Adverse event was reported on Feb 25, 2009 by a Male patient taking Oncaspar (View Usage) (Dosage: 4825 Iu; Im) was diagnosed with b precursor type acute leukaemia and. Location: UNITED STATES , 16 years of age, weighting 157.2 lb, Patient had the following side effects: pancreatitis. During the same period patient was treated with CYTOXAN (View Cytoxan Review and Cytoxan Label ), ARA C (View Ara-c Review and Ara-c Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ). Patient was hospitalized.

6663056-1 | Anaphylactic Reaction, Cough, Rash, Throat Irritation, Throat Tightness
on Feb 11, 2009 Female patient from UNITED STATES , child 12 years of age, was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: anaphylactic reaction, cough, rash (What is rash?), throat irritation, throat tightness. Oncaspar dosage: .

6663055-X | Anaphylactic Reaction, Dyspnoea, Hypotension, Loss Of Consciousness, Wheezing
on Feb 04, 2009 Female patient from UNITED STATES , 16 years of age, weighting 108.6 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic reaction, dyspnoea, hypotension, loss of consciousness, wheezing. Oncaspar dosage: 2500 Mg/m**2; Im. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), BACTRIM DS (View Bactrim Ds Review and Bactrim Ds Label ), AMBIEN (View Ambien Review and Ambien Label ), LEXAPRO (View Lexapro Review and Lexapro Label ). Patient was hospitalized.

6661527-5 | Anaemia, Dehydration, Haematemesis, Hyperbilirubinaemia, Hyperglycaemia, Infection, Leukopenia, Mucosal Inflammation, Oropharyngeal Pain
Patient was taking Oncaspar (View Usage). Patient had the following side effects: anaemia, dehydration, haematemesis, hyperbilirubinaemia, hyperglycaemia, infection (What is infection?), leukopenia, mucosal inflammation, oropharyngeal pain on Mar 18, 2010 from UNITED STATES Additional patient health information: Male patient , child 9 years of age, weighting 95.02 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 3575 Iu; X1; Iv; 3300 Iu; X1; Iv. During the same period patient was treated with METHOTREXATE (130 Mg; Xl; Iv; 15 Mg;x1; Inth) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6648520-3 | Enterococcal Sepsis, Urinary Tract Infection
Adverse event was reported on Mar 05, 2010 by a Male patient taking Oncaspar (View Usage) (Dosage: X1) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , 60 years of age, weighting 184.1 lb, After Oncaspar was administered, patient had the following side effects: enterococcal sepsis, urinary tract infection (What is urinary tract infection?). During the same period patient was treated with DAUNORUBICIN HCL (Qd;iv) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (Qw;iv) (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (Qd;po) (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

6648459-3 | Abdominal Pain Upper, Cholecystitis, Cholelithiasis, Fall, Fatigue, Jaundice, Neutropenia
on Mar 09, 2010 Female patient from UNITED STATES , 80 years of age, weighting 124.8 lb, was diagnosed with diffuse large b-cell lymphoma and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, cholecystitis, cholelithiasis, fall (What is fall?), fatigue, jaundice (What is jaundice?), neutropenia. Oncaspar dosage: 4000 Iu; Qow;iv. During the same period patient was treated with DOXIL (32 Mg; Qow; Iv) (View Doxil Review and Doxil Label ), DECADRON (View Decadron Review and Decadron Label ). Patient was hospitalized.

6637633-8 | Abdominal Pain Lower, Blood Phosphorus Increased, Headache, Hyperbilirubinaemia, Hyperglycaemia, Hyperuricaemia, Hypocalcaemia, Oropharyngeal Pain, Photosensitivity Reaction
on Mar 04, 2010 Male patient from UNITED STATES , 17 years of age, weighting 146.4 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). Patient had the following side effects: abdominal pain lower, blood phosphorus increased, headache (What is headache?), hyperbilirubinaemia, hyperglycaemia, hyperuricaemia, hypocalcaemia, oropharyngeal pain, photosensitivity reaction. Oncaspar dosage: 2500 Iu*mg; I V, 4500 Iu; X1; Iv. During the same period patient was treated with METHOTREXATE (15 Mg; Inth; 810 Mg; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (6 Mg; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6631118-0 | Apnoea, Haemorrhagic Stroke, Superior Sagittal Sinus Thrombosis
Patient was taking Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: apnoea, haemorrhagic stroke, superior sagittal sinus thrombosis on Mar 02, 2010 from UNITED STATES Additional patient health information: Male patient , child 11 years of age, weighting 78.93 lb, was diagnosed with t-cell type acute leukaemia and. Oncaspar dosage: 3025 Iu, Im. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6631099-X | Blood Lactic Acid Increased, Cerebral Infarction, Cerebrovascular Accident, Coagulopathy, Hypertension, Intracranial Venous Sinus Thrombosis, Leukaemic Infiltration, Pyrexia
Adverse event was reported on Mar 20, 2010 by a Female patient taking Oncaspar (View Usage) (Dosage: 4250 Iu;x1;iv) was diagnosed with b precursor type acute leukaemia and. Location: UNITED STATES , child 12 years of age, weighting 143.3 lb, Patient experienced the following unwanted or unexpected effects: blood lactic acid increased, cerebral infarction, cerebrovascular accident, coagulopathy, hypertension, intracranial venous sinus thrombosis, leukaemic infiltration, pyrexia.

6620804-4 | Cholecystitis, Cholelithiasis, Fall, Fatigue
on Feb 23, 2010 Female patient from UNITED STATES , 80 years of age, weighting 124.8 lb, was diagnosed with diffuse large b-cell lymphoma and was treated with Oncaspar (View Usage). Patient had the following side effects: cholecystitis, cholelithiasis, fall (What is fall?), fatigue. Oncaspar dosage: 4000 Iu; Qow; Iv. During the same period patient was treated with DOXIL (32 Mg Qow; Iv) (View Doxil Review and Doxil Label ), DECADRON (View Decadron Review and Decadron Label ). Patient was hospitalized.

6611942-0 | Face Oedema, Hypotension, Lip Swelling, Tachycardia, Vomiting
on Feb 26, 2010 Male patient from UNITED STATES , child 11 years of age, weighting 113.8 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: face oedema, hypotension, lip swelling, tachycardia, vomiting. Oncaspar dosage: 3675 Iu Over 2 Hr 2500mg/m2 Once Iv. During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), METHOTREXATE AND VINCRISTINE (View Methotrexate And Vincristine Review and Methotrexate And Vincristine Label ), PEG ASP (View Peg-asp Review and Peg-asp Label ). Patient was hospitalized.

6611697-X | Urticaria
Patient was taking Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: urticaria on Feb 26, 2010 from UNITED STATES Additional patient health information: Female patient , child 4 years of age, weighting 37.70 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 862.5 Iu Im -2500mg/m2- X 2 Shots Im. During the same period patient was treated with PEG ASP LOT# 8113A (View Peg-asp - Lot# 8113a Review and Peg-asp - Lot# 8113a Label ).

6611695-6 | Infusion Related Reaction
Adverse event was reported on Feb 26, 2010 by a Male patient taking Oncaspar (View Usage) (Dosage: 2850 Iu Over 2 Hr -2500mg/m2- Once Iv) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 12 years of age, weighting 80.47 lb, Patient had the following side effects: infusion related reaction. During the same period patient was treated with PEG ASP LOT #9061A (View Peg-asp Lot #9061a Review and Peg-asp Lot #9061a Label ), PEG ASP LOT # 9066A (View Peg-asp Lot # 9066a Review and Peg-asp Lot # 9066a Label ).

6607049-9 | Brain Contusion, Brain Oedema, Cardiac Arrest, Intracranial Pressure Increased, Subarachnoid Haemorrhage
on Feb 10, 2010 Male patient from UNITED STATES , 60 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncaspar (View Usage). After Oncaspar was administered, patient had the following side effects: brain contusion, brain oedema, cardiac arrest (What is cardiac arrest?), intracranial pressure increased, subarachnoid haemorrhage. Oncaspar dosage: 2500 Iu/kg;x1;iv; 2500 Iu/kg; Iv. During the same period patient was treated with CALCIUM (View Calcium Review and Calcium Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), FLONASE (View Flonase Review and Flonase Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), PREVACID (View Prevacid Review and Prevacid Label ), CLARITIN (View Claritin Review and Claritin Label ). Patient was hospitalized.

6597647-3 | Blood Lactic Acid Increased, Coagulopathy, Hypertension, Leukaemic Infiltration, Mental Status Changes, Pyrexia
on Feb 19, 2010 Female patient from UNITED STATES , child 12 years of age, was diagnosed with acute leukaemia and was treated with Oncaspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood lactic acid increased, coagulopathy, hypertension, leukaemic infiltration, mental status changes, pyrexia. Oncaspar dosage: 4250 Iu Once Iv Drip.

6597176-7 | Abdominal Pain Lower, Back Pain, Condition Aggravated, Headache, Hyperbilirubinaemia, Hyperglycaemia, Hyperuricaemia, Hypoalbuminaemia, Hypocalcaemia
Patient was taking Oncaspar (View Usage). Patient had the following side effects: abdominal pain lower, back pain (What is back pain?), condition aggravated, headache (What is headache?), hyperbilirubinaemia, hyperglycaemia, hyperuricaemia, hypoalbuminaemia, hypocalcaemia on Jan 29, 2010 from UNITED STATES Additional patient health information: Male patient , 17 years of age, weighting 146.4 lb, was diagnosed with acute lymphocytic leukaemia and. Oncaspar dosage: 2500 Iu*m2; ; Iv, 4500 Iu; X1; Iv. During the same period patient was treated with METHOTREXATE (15 Mg; ; Inth, 810 Mg; ; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (6 Mg; ; Iv) (View Vincristine Review and Vincristine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.